Evaluate the Effect of Obicetrapib in Patients With HeFH on Top of Maximum Tolerated Lipid-Modifying Therapies.

NCT05425745 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

354

Enrollment

INDUSTRY

Sponsor class

Conditions

Dyslipidemias
High Cholesterol
Hypercholesterolemia
Familial Hypercholesterolemia
Lipid Metabolism Disorder
Metabolic Disease
Lipid Metabolism, Inborn Errors
Genetic Disease, Inborn
Hyperlipoproteinemias

Interventions

DRUG: Obicetrapib
DRUG: Placebo

Sponsor

NewAmsterdam Pharma